Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Erlotinib and gemcitabine combined chemotherapy is becoming the treatment of choice in advanced pancreatic cancer. We evaluated the effectiveness of treatment with erlotinib plus gemcitabine and the prognostic factors for chemotherapeutic response in Korean pancreatic cancer patients. Methods: Sixty-nine patients with advanced pancreatic cancer who were treated with daily erlotinib 100mg orally and gemcitabine 1,000 mg/m2/30 min intravenous infusion on days 1, 8, and 15 of each 4-week cycle from 2006 to 2009 were included in this study. This study was a phase II single-center trial. Results: All 69 patients with advanced pancreatic cancer were chemotherapy-naïve. The objective response rate was 18.8%, and the overall tumor-stabilization rate was 49.2%. The median overall survival was 7.7 months (95% confidence interval [CI], 6.0 to 9.4 months). The median progression-free survival was 1.9months (95% CI, 1.4 to 2.5 months). Prognostic factors for good chemotherapeutic response were good performance status and the presence of skin rash during chemotherapy. Patients with lower performance scores showed worse chemotherapeutic responses (odds ratio [OR], 7.6; 95% CI, 2.4to 24.8). Poor responses were predicted by the absence of skin rash during chemotherapy (OR, 3.0; 95% CI, 1.4 to 6.3). Conclusions: Erlotinib and gemcitabine chemotherapy is a tolerable treatment regimen and has a favorable therapeutic effect in Korean patients with advanced pancreatic cancer
Abstract
Background/Aims: Erlotinib and gemcitabine combined chemotherapy is becoming the treatment of choice in advanced pancreatic cancer. We evaluated the effectiveness of treatment with erlotinib plus gemcitabine and the prognostic factors for chemotherapeutic response in Korean pancreatic cancer patients. Methods: Sixty-nine patients with advanced pancreatic cancer who were treated with daily erlotinib 100mg orally and gemcitabine 1,000 mg/m2/30 min intravenous infusion on days 1, 8, and 15 of each 4-week cycle from 2006 to 2009 were included in this study. This study was a phase II single-center trial. Results: All 69 patients with advanced pancreatic cancer were chemotherapy-naïve. The objective response rate was 18.8%, and the overall tumor-stabilization rate was 49.2%. The median overall survival was 7.7 months (95% confidence interval [CI], 6.0 to 9.4 months). The median progression-free survival was 1.9months (95% CI, 1.4 to 2.5 months). Prognostic factors for good chemotherapeutic response were good performance status and the presence of skin rash during chemotherapy. Patients with lower performance scores showed worse chemotherapeutic responses (odds ratio [OR], 7.6; 95% CI, 2.4to 24.8). Poor responses were predicted by the absence of skin rash during chemotherapy (OR, 3.0; 95% CI, 1.4 to 6.3). Conclusions: Erlotinib and gemcitabine chemotherapy is a tolerable treatment regimen and has a favorable therapeutic effect in Korean patients with advanced pancreatic cancer
참고문헌 (18)
- Van Cutsem E, "Systemic treatment of pancreatic cancer", Eur J Gastroenterol Hepatol, 16, pp.265~274 (2004)
- Lowenfels AB, "Epidemiology and prevention of pancreatic cancer", Jpn J Clin Oncol, 34, pp.238~244 (2004)
- Burris HA 3rd, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial", J Clin Oncol, 15, pp.2403~2413 (1997)
- Berlin JD, "Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297", J Clin Oncol, 20, pp.3270~3275 (2002)
- Carmichael J, "Phase II study of gemcitabine in patients with advanced pancreatic cancer", Br J Cancer, 73, pp.101~105 (1996)
- "Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma", PANCREATOLOGY, 6, pp.635~641 (2006), KARGER
- Bareschino MA, "Erlotinib in cancer treatment", Ann Oncol, (18 Suppl 6), pp.v35~vi41 (2007)
- Ciardiello F, "EGFR antagonists in cancer treatment", N Engl J Med, 358, pp.1160~1174 (2008)
- Cataldo VD, "Treatment of non-small-cell lung cancer with erlotinib or gefitinib", N Engl J Med, 364, pp.947~955 (2011)
- Thatcher N, "Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)", Lancet, 366, pp.1527~1537 (2005)
- Shepherd FA, "Erlotinib in previously treated non-small-cell lung cancer", N Engl J Med, 353, pp.123~132 (2005)
- Moore MJ, "Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group", J Clin Oncol, 25, pp.1960~1966 (2007)
- Sandler AB, "Nondermatologic adverse events associated with anti-EGFR therapy", Oncology (Williston Park), 20(5 Suppl 2), pp.35~40 (2006)
- Boeck S, "Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer", Anticancer Drugs, 18, pp.1109~1111 (2007)
- Lynch TJ Jr, "Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management", Oncologist, 12, pp.610~621 (2007)
- Ando M, "Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib", J Clin Oncol, 24, pp.2549~2556 (2006)
- Miksad RA, "Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?", J Clin Oncol, 25, pp.4506~4507 (2007)
- da Cunha Santos G, "Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3", Cancer, 116, pp.5599~5607 (2010)